Wuytack Francesca, Smith Valerie, Cleary Brian J
School of Nursing and Midwifery, Trinity College Dublin, D'Olier Street, Dublin, Ireland, 2.
Cochrane Database Syst Rev. 2016 Jul 14;7(7):CD011352. doi: 10.1002/14651858.CD011352.pub2.
Many women experience perineal pain after childbirth, especially after having sustained perineal trauma. Perineal pain-management strategies are thus an important part of postnatal care. Non-steroidal anti-inflammatory drugs (NSAIDs) are a commonly used type of medication in the management of postpartum pain and their effectiveness and safety should be assessed.
To determine the effectiveness of a single dose of an oral NSAID for relief of acute perineal pain in the early postpartum period.
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 March 2016), OpenSIGLE, ProQuest Dissertations and Theses, the ISRCTN Registry and ClinicalTrials.gov (31 March 2016). We also reviewed reference lists of retrieved papers and contacted experts in the field.
Randomised controlled trials (RCTs) assessing a single dose of a NSAID versus a single dose of placebo, paracetamol or another NSAID for women with perineal pain in the early postpartum period. Quasi-RCTs and cross-over trials were excluded.
Two review authors (FW and VS) independently assessed all identified papers for inclusion and risk of bias. Any discrepancies were resolved through discussion and consensus. Data extraction, including calculations of pain relief scores, was also conducted independently by two review authors and checked for accuracy.
We included 28 studies that examined 13 different NSAIDs and involved 4181 women (none of whom were breastfeeding). Studies were published between 1967 and 2013, with the majority published in the 1980s. Of the 4181 women involved in the studies, 2642 received a NSAID and 1539 received placebo or paracetamol. Risk of bias was generally unclear due to poor reporting, but in most studies the participants and personnel were blinded, outcome data were complete and the outcomes that were specified in the methods section were reported.None of the included studies reported on any of this review's secondary outcomes: prolonged hospitalisation or re-hospitalisation due to perineal pain; breastfeeding (fully or mixed) at discharge; breastfeeding (fully or mixed) at six weeks; perineal pain at six weeks; maternal views; postpartum depression; instrumental measures of disability due to perineal pain. NSAID versus placeboCompared to women who received a placebo, more women who received a single dose NSAID achieved adequate pain relief at four hours (risk ratio (RR) 1.91, 95% confidence interval (CI) 1.64 to 2.23, 10 studies, 1573 participants (low-quality evidence)) and adequate pain relief at six hours (RR 1.92, 95% CI 1.69 to 2.17, 17 studies, 2079 participants (very low-quality evidence)). Women who received a NSAID were also less likely to need additional analgesia compared to women who received placebo at four hours (RR 0.39, 95% CI 0.26 to 0.58, four studies, 486 participants (low-quality evidence)) and at six hours after initial administration (RR 0.32, 95% CI 0.26 to 0.40, 10 studies, 1012 participants (low-quality evidence)). Fourteen maternal adverse effects were reported in the NSAID group (drowsiness (5), abdominal discomfort (2), weakness (1), dizziness (2), headache (2), moderate epigastralgia (1), not specified (1)) and eight in the placebo group (drowsiness (2), light headed (1), nausea (1), backache (1), dizziness (1), epigastric pain (1), not specified (1)), although not all studies assessed adverse effects. There was no difference in overall maternal adverse effects between NSAIDs and placebo at six hours post-administration (RR 1.38, 95% CI 0.71 to 2.70, 13 studies, 1388 participants (very low-quality evidence)). One small study (with two treatment arms) assessed maternal adverse effects at four hours post-administration, but there were no maternal adverse effects observed (one study, 90 participants (low-quality evidence)). Neonatal adverse effects were not assessed in any of the included studies. NSAID versus paracetamolNSAIDs versus paracetamol were also more effective for adequate pain relief at four hours (RR 1.54, 95% CI 1.07 to 2.22, three studies, 342 participants) but not at six hours post-administration. There was no difference in the need for additional analgesia between the two groups at four hours (RR 0.55, 95% CI 0.27 to 1.13, one study, 73 participants), but women in the NSAID group were less likely to need any additional analgesia at six hours (RR 0.28, 95% CI 0.12 to 0.67, one study, 59 participants). No maternal adverse effects were reported four hours after drug administration (one study). Six hours post-administration, there was no difference between the groups in the number of maternal adverse effects (RR 0.74, 95% CI 0.27 to 2.08, three studies, 300 participants), with one case of pruritis in the NSAID group and one case of sleepiness in the paracetamol group. Neonatal adverse effects were not assessed in any of the included studies.Comparisons of different NSAIDs and different doses of the same NSAID did not demonstrate any differences in their effectiveness on any of the primary outcome measures; however, few data were available on some NSAIDs.
AUTHORS' CONCLUSIONS: In women who are not breastfeeding and who sustained perineal trauma, NSAIDs (compared to placebo) provide greater pain relief for acute postpartum perineal pain and fewer women need additional analgesia when treated with a NSAID. However, the risk of bias was unclear for many of the included studies, adverse effects were often not assessed and breastfeeding women were not included in the studies. The overall quality of the evidence (GRADE) was low with the evidence for all outcomes rated as low or very low. The main reasons for downgrading were inclusion of studies with high risk of bias and inconsistency of findings of individual studies.NSAIDs also appear to be more effective in providing relief for perineal pain than paracetamol, but few studies were included in this analysis.Future studies should examine NSAIDs' adverse effects profile including neonatal adverse effects and the compatibility of NSAIDs with breastfeeding, and assess other important secondary outcomes of this review. Moreover, studies mostly included women who had episiotomies. Future research should consider women with and without perineal trauma, including perineal tears. High-quality studies should be conducted to further assess the efficacy of NSAIDs versus paracetamol and the efficacy of multimodal treatments.
许多女性在产后会经历会阴疼痛,尤其是在遭受会阴创伤后。因此,会阴疼痛管理策略是产后护理的重要组成部分。非甾体抗炎药(NSAIDs)是产后疼痛管理中常用的一类药物,其有效性和安全性应得到评估。
确定单剂量口服NSAIDs缓解产后早期急性会阴疼痛的有效性。
我们检索了Cochrane妊娠与分娩组试验注册库(2016年3月31日)、OpenSIGLE、ProQuest学位论文数据库、ISRCTN注册库和ClinicalTrials.gov(2016年3月31日)。我们还查阅了检索到的论文的参考文献列表,并联系了该领域的专家。
评估单剂量NSAIDs与单剂量安慰剂、对乙酰氨基酚或另一种NSAIDs用于产后早期会阴疼痛女性的随机对照试验(RCTs)。排除准RCTs和交叉试验。
两位综述作者(FW和VS)独立评估所有已识别的论文是否符合纳入标准和偏倚风险。任何差异通过讨论和达成共识来解决。数据提取,包括疼痛缓解评分的计算,也由两位综述作者独立进行,并检查其准确性。
我们纳入了28项研究,这些研究考察了13种不同的NSAIDs,涉及4181名女性(均未进行母乳喂养)。研究发表于1967年至2013年之间,大多数发表于20世纪80年代。在参与研究的4181名女性中,2642名接受了NSAIDs,1539名接受了安慰剂或对乙酰氨基酚。由于报告质量差,偏倚风险通常不明确,但在大多数研究中,参与者和研究人员是盲法的,结局数据完整,并且报告了方法部分中指定的结局。纳入的研究均未报告本综述的任何次要结局:因会阴疼痛导致的住院时间延长或再次住院;出院时的母乳喂养情况(完全或混合喂养);六周时的母乳喂养情况(完全或混合喂养);六周时的会阴疼痛情况;产妇的观点;产后抑郁;因会阴疼痛导致的残疾的工具性测量。NSAIDs与安慰剂相比与接受安慰剂的女性相比,接受单剂量NSAIDs的女性在4小时时更能达到充分的疼痛缓解(风险比(RR)1.91,95%置信区间(CI)1.64至2.23,10项研究,1573名参与者(低质量证据)),在6小时时也更能达到充分的疼痛缓解(RR 1.92,95%CI 1.69至2.17,17项研究,2079名参与者(极低质量证据))。与接受安慰剂的女性相比,接受NSAIDs的女性在4小时时也不太可能需要额外的镇痛(RR 0.39,95%CI 0.26至0.58,4项研究,486名参与者(低质量证据)),在初次给药后6小时时也是如此(RR 0.32,95%CI 0.26至0.40,10项研究,1012名参与者(低质量证据))。NSAIDs组报告了14例产妇不良反应(嗜睡(5例)、腹部不适(2例)、虚弱(1例)、头晕(2例)、头痛(2例)、中度上腹部疼痛(1例)、未明确说明(1例)),安慰剂组报告了8例(嗜睡(2例)、头晕(1例)、恶心(1例)、背痛(1例)、头晕(1例)、上腹部疼痛(1例)、未明确说明(1例)),尽管并非所有研究都评估了不良反应。给药后6小时,NSAIDs组和安慰剂组的总体产妇不良反应无差异(RR 1.38,95%CI 0.71至2.70,13项研究,1388名参与者(极低质量证据))。一项小型研究(有两个治疗组)评估了给药后4小时的产妇不良反应,但未观察到产妇不良反应(1项研究,90名参与者(低质量证据))。纳入的研究均未评估新生儿不良反应。NSAIDs与对乙酰氨基酚相比NSAIDs与对乙酰氨基酚在4小时时对充分缓解疼痛也更有效(RR 1.54,95%CI 1.07至2.22,3项研究),但在给药后6小时时并非如此。两组在4小时时对额外镇痛的需求无差异(RR 0.55,95%CI 0.27至1.13,1项研究,73名参与者),但NSAIDs组的女性在6小时时不太可能需要任何额外的镇痛(RR 0.28,95%CI 0.12至0.67,1项研究,59名参与者)。给药后4小时未报告产妇不良反应(1项研究)。给药后6小时时,两组产妇不良反应的数量无差异(RR 0.74,95%CI 0.27至2.08,3项研究,300名参与者),NSAIDs组有1例瘙痒,对乙酰氨基酚组有1例嗜睡。纳入的研究均未评估新生儿不良反应。不同NSAIDs以及同一NSAIDs不同剂量之间的比较在任何主要结局指标的有效性方面均未显示出差异;然而,关于某些NSAIDs的数据很少。
在未进行母乳喂养且遭受会阴创伤的女性中,NSAIDs(与安慰剂相比)能为产后急性会阴疼痛提供更大程度的缓解,并且使用NSAIDs治疗时需要额外镇痛的女性更少。然而,许多纳入研究的偏倚风险不明确,不良反应常常未被评估,且研究未纳入母乳喂养的女性。证据的总体质量(GRADE)较低,所有结局的证据等级均为低或极低。降级的主要原因是纳入了偏倚风险高的研究以及个别研究结果的不一致性。NSAIDs在缓解会阴疼痛方面似乎也比对乙酰氨基酚更有效,但该分析纳入的研究较少。未来的研究应检查NSAIDs的不良反应情况,包括新生儿不良反应以及NSAIDs与母乳喂养的兼容性,并评估本综述的其他重要次要结局。此外,研究大多纳入了接受会阴切开术的女性。未来的研究应考虑有和没有会阴创伤的女性,包括会阴撕裂。应进行高质量的研究以进一步评估NSAIDs与对乙酰氨基酚的疗效以及多模式治疗的疗效。